within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ04_Sutimlimab;
model Sutimlimab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AJ04;

  annotation(Documentation(
    info ="<html><body><p>Sutimlimab is a humanized monoclonal antibody that inhibits complement component C1s. It is used primarily in the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. Sutimlimab is approved for use in adults with CAD to prevent hemolysis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients (majority female, mean age ~70 years) with cold agglutinin disease after intravenous administration.</p><h4>References</h4><ol><li><p>Bartko, J, et al., &amp; Jilma, B (2018). A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. <i>Clinical pharmacology and therapeutics</i> 104(4) 655â€“663. DOI:<a href=&quot;https://doi.org/10.1002/cpt.1111&quot;>10.1002/cpt.1111</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29737533/&quot;>https://pubmed.ncbi.nlm.nih.gov/29737533</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Sutimlimab;
